

ASX Announcement

Racura Raised \$34.3m to Advance Three Oncology Clinical Trials

- Racura has raised in total \$34.3m to fund three clinical trials in AML, EGFRm lung cancer, and chemotherapy-related cardioprotection in solid tumour patients
- We thank all shareholders, new and existing, for their continued support

16 June 2026

Racura Oncology Limited (“Racura” or “Company”) is pleased to announce that, following a series of fundraising initiatives strongly supported by new and existing shareholders, it has raised a total of \$34.3 million. These funds have provided the Company with a strong cash balance allowing it to fully fund its announced RC220 clinical programs in Acute Myeloid Leukaemia (AML), Epidermal Growth Factor Receptor mutant (EGFRm) non-small cell lung cancer, and anthracycline cardioprotection in solid tumour patients, as well as providing general working capital.

The Company had previously entered into an Underwriting Agreement for any Piggyback Options shortfall (ASX Announcement: 28 May 2026). The Agreement permitted full or partial placement of any shortfall at the Company’s discretion. By mutual agreement with the Underwriter, the Company has elected to partially place 509,205 of the 631,201 shortfall Options to limit shareholder dilution and contributing an additional \$636,506.25.

Since June 2024, Racura has raised \$34.3 million through Bonus and Piggyback Option conversions (ASX Announcements: 6 June 2024 & 4 June 2026), private placements (ASX Announcements: 6 December 2025 & 4 June 2026), and Option underwriting. No broker or underwriter fees were paid in connection with these raisings.

CEO and Managing Director, Dr Daniel Tillett, said: *“We are deeply grateful for the enormous support shown by our shareholders. Raising more than \$34 million directly from our shareholders over the past two years demonstrates exceptional confidence in us and our mission. We look forward to updating investors on RC220’s clinical progress in the coming months.”*

-ENDS-

About Racura Oncology

Racura Oncology (ASX: RAC) is a Phase 3 stage clinical biopharmaceutical company with a mission to silence cancer.

Racura's lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent silencing of the important cancer growth regulator MYC. (E,E)-bisantrene has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over (E,E)-bisantrene.

Racura is advancing a proprietary formulation of (E,E)-bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a Phase 3 clinical program in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.

Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively exploring partnerships, licence agreements, or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com.

If you have any questions on this announcement, or any past Racura announcements please visit our [Interactive Announcements](#) page.

Racura encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by

Daniel Tillett, CEO

info@racuraoncology.com

Media Contact

Kitty O'Neill

kitty.oneill@irdepartment.com.au